Benzinga | Sep 13, 2021 08:57AM EDT

Cantor Fitzgerald Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $165

Cantor Fitzgerald analyst Charles Duncan maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Overweight and raises the price target from $151 to $165.